 | • レポートコード：MRC2304E034 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、229ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社発行の当市場調査レポートでは、2021年に2,182.29百万ドルであった世界のCRISPR＆Cas遺伝子市場規模が、2022年に2,883.43百万ドルに達し、2027年には11,705.15百万ドルまでCAGR 32.30％で成長すると見込まれています。当レポートは、CRISPR＆Cas遺伝子の世界市場を多角的に調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、コンポーネント別（製品、サービス）分析、用途別（農業、生物医学）分析、エンドユーザー別（学術＆政府研究機関、バイオテクノロジー＆製薬会社、受託研究機関（CRO））分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の項目をまとめています。また、当書は、Addgene、Astrazeneca、Beam Therapeutics、Beckman Coulter, Inc.、Calyxt, Inc.、Caribou Biosciences, Inc.、Cellectis、Cibus、CRISPR Therapeutics、Danaher Corporation、Editas Medicine, Inc.、eGenesis、Genscriptなどの企業情報を含んでいます。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のCRISPR＆Cas遺伝子市場規模：コンポーネント別 - 製品の市場規模 - サービスの市場規模 ・世界のCRISPR＆Cas遺伝子市場規模：用途別 - 農業における市場規模 - 生物医学における市場規模 ・世界のCRISPR＆Cas遺伝子市場規模：エンドユーザー別 - 学術＆政府研究機関における市場規模 - バイオテクノロジー＆製薬会社における市場規模 - 受託研究機関（CRO）における市場規模 ・世界のCRISPR＆Cas遺伝子市場規模：地域別 - 南北アメリカのCRISPR＆Cas遺伝子市場規模 アメリカのCRISPR＆Cas遺伝子市場規模 カナダのCRISPR＆Cas遺伝子市場規模 ブラジルのCRISPR＆Cas遺伝子市場規模 … - アジア太平洋のCRISPR＆Cas遺伝子市場規模 日本のCRISPR＆Cas遺伝子市場規模 中国のCRISPR＆Cas遺伝子市場規模 インドのCRISPR＆Cas遺伝子市場規模 韓国のCRISPR＆Cas遺伝子市場規模 台湾のCRISPR＆Cas遺伝子市場規模 … - ヨーロッパ/中東/アフリカのCRISPR＆Cas遺伝子市場規模 イギリスのCRISPR＆Cas遺伝子市場規模 ドイツのCRISPR＆Cas遺伝子市場規模 フランスのCRISPR＆Cas遺伝子市場規模 ロシアのCRISPR＆Cas遺伝子市場規模 … - その他地域のCRISPR＆Cas遺伝子市場規模 ・競争状況 ・企業情報 |
The Global CRISPR & Cas Genes Market size was estimated at USD 2,182.29 million in 2021 and expected to reach USD 2,883.43 million in 2022, and is projected to grow at a CAGR 32.30% to reach USD 11,705.15 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the CRISPR & Cas Genes to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Component, the market was studied across Product and Service. The Product is further studied across Antibodies, Design Tool, Kits & Enzymes, and Libraries. The Kits & Enzymes is further studied across DNA-free Cas and Vector-based Cas. The Service is further studied across Cell Line Engineering, DNA synthesis, gRNA Design, and Microbial Gene Editing.
Based on Application, the market was studied across Agricultural and Biomedical. The Biomedical is further studied across Disease Model Studies, Epigenetics, Functional Genomics, and Genome Engineering.
Based on End-user, the market was studied across Academics & Government Research Institutes, Biotechnology & Pharmaceutical Companies, and Contract Research Organizations (CROs).
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for CRISPR & Cas Genes market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the CRISPR & Cas Genes Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global CRISPR & Cas Genes Market, including Addgene, Astrazeneca, Beam Therapeutics, Beckman Coulter, Inc., Calyxt, Inc., Caribou Biosciences, Inc., Cellectis, Cibus, CRISPR Therapeutics, Danaher Corporation, Editas Medicine, Inc., eGenesis, Genscript, Hera Biolabs, Horizon Discovery Group Plc, Inscripta, Inc., Integrated Dna Technologies, Inc., Intellia Therapeutics, Inc., Lonza, Mammoth Biosciences, Merck Kgaa, Mirus Bio Llc, New England Biolabs, Origene Technologies, Inc., Plantedit, Recombinetics, Inc., Sigma – Aldrich Co. Llc, Synthego, Takara Bio, Inc., Thermo Fisher Scientific, Inc., and Vertex Pharmaceuticals Incorporated.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global CRISPR & Cas Genes Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global CRISPR & Cas Genes Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global CRISPR & Cas Genes Market?
4. What is the competitive strategic window for opportunities in the Global CRISPR & Cas Genes Market?
5. What are the technology trends and regulatory frameworks in the Global CRISPR & Cas Genes Market?
6. What is the market share of the leading vendors in the Global CRISPR & Cas Genes Market?
7. What modes and strategic moves are considered suitable for entering the Global CRISPR & Cas Genes Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Adoption of technology in various biotechnology areas
5.1.1.2. Technological advancements in the genome editing platform
5.1.1.3. Rising awareness regarding multiple CRISPR-Cas applications in various fields such as drug discovery, biomedical research, and non-transgenic bleeding
5.1.2. Restraints
5.1.2.1. Off-target effects of CRISPR technology
5.1.3. Opportunities
5.1.3.1. Evolution of anti-CRISPR protein
5.1.3.2. Ongoing competition for CRISPR commercialization
5.1.4. Challenges
5.1.4.1. Patent landscape and dispute
5.2. Cumulative Impact of COVID-19
6. CRISPR & Cas Genes Market, by Component
6.1. Introduction
6.2. Product
6.3.1. Antibodies
6.3.2. Design Tool
6.3.3. Kits & Enzymes
6.3.4.1. DNA-free Cas
6.3.4.2. Vector-based Cas
6.3.4. Libraries
6.3. Service
6.4.1. Cell Line Engineering
6.4.2. DNA synthesis
6.4.3. gRNA Design
6.4.4. Microbial Gene Editing
7. CRISPR & Cas Genes Market, by Application
7.1. Introduction
7.2. Agricultural
7.3. Biomedical
7.4.1. Disease Model Studies
7.4.2. Epigenetics
7.4.3. Functional Genomics
7.4.4. Genome Engineering
8. CRISPR & Cas Genes Market, by End-user
8.1. Introduction
8.2. Academics & Government Research Institutes
8.3. Biotechnology & Pharmaceutical Companies
8.4. Contract Research Organizations (CROs)
9. Americas CRISPR & Cas Genes Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific CRISPR & Cas Genes Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa CRISPR & Cas Genes Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Addgene
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Astrazeneca
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Beam Therapeutics
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Beckman Coulter, Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Calyxt, Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Caribou Biosciences, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Cellectis
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Cibus
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. CRISPR Therapeutics
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Danaher Corporation
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Editas Medicine, Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. eGenesis
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Genscript
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Hera Biolabs
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Horizon Discovery Group Plc
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Inscripta, Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Integrated Dna Technologies, Inc.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Intellia Therapeutics, Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Lonza
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Mammoth Biosciences
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Merck Kgaa
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Mirus Bio Llc
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. New England Biolabs
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Origene Technologies, Inc.
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Plantedit
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. Recombinetics, Inc.
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
13.27. Sigma – Aldrich Co. Llc
13.27.1. Business Overview
13.27.2. Key Executives
13.27.3. Product & Services
13.28. Synthego
13.28.1. Business Overview
13.28.2. Key Executives
13.28.3. Product & Services
13.29. Takara Bio, Inc.
13.29.1. Business Overview
13.29.2. Key Executives
13.29.3. Product & Services
13.30. Thermo Fisher Scientific, Inc.
13.30.1. Business Overview
13.30.2. Key Executives
13.30.3. Product & Services
13.31. Vertex Pharmaceuticals Incorporated
13.31.1. Business Overview
13.31.2. Key Executives
13.31.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing